CervoMed’s Phase 2 miss; NICE to cover Santhera’s Duchenne drug

Plus, news about Lava Therapeutics, Recursion and Aqemia: CervoMed’s dementia drug disappoints in Phase 2: The drugmaker’s neflamapimod missed both the primary and key secondary endpoints in a mid-stage trial of ...